IMPACT BIOMEDICAL INC.
About IMPACT BIOMEDICAL INC.
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $32.0K
- Net income
- -$11.8M
- Total assets
- $17.4M
- Market cap
- $61.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$4.3M
- Income tax
- -$2.6M
- Net income
- -$11.9M
- EPS (basic)
- $-0.38
- EPS (diluted)
- $-0.38
Balance sheet
- Total assets
- $17.4M
- Current assets
- $411.0K
- Total liabilities
- $1.9M
- Current liabilities
- $1.2M
- Shareholders’ equity
- $15.6M
Cash flow
- Operating cash flow
- -$1.9M
- Investing cash flow
- $3.0K
- Financing cash flow
- -$109.0K
- Net cash flow
- -$2.0M
Statements via Polygon.io (SEC filings)
- Market cap
- $61.1M
- EPS (diluted)
- $-0.38
- Shares outstanding
- 109.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 16, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $11.8M in FY2025.
- Trading 65% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review IMPACT BIOMEDICAL INC..
Write a review
News about IMPACT BIOMEDICAL INC.
News & sentiment via Polygon.io
